Utmos Adverse Reactions

Adverse drug reactions of pioglitazone occurring in 5% or more of patients include upper respiratory tract infection, headache, sinusitis, myalgia, tooth disorder, aggravation of diabetes mellitus and pharyngitis. Adverse effects generally were similar with pioglitazone monotherapy versus combined therapy with sulfonylureas, metformin, or insulin; however, edema was more common during pioglitazone therapy than placebo.
Anemia was reported in ≤ 2% of patients treated with pioglitazone plus sulfonylurea, metformin or insulin. This symptom was mild to moderate and usually did not require drug discontinuance.
Dyspnea and either weight gain or edema have occurred during combination therapy of pioglitazone and insulin; in some cases, diuretic therapy was required to treat symptoms.
Sporadic, elevations in creatine phosphokinase levels were observed.
In clinical trials, hypoglycemia occurred in 2% of patients receiving pioglitazone in combination with a sulfonylurea and in 8 or 15% of those receiving pioglitazone 15 mg or 30 mg, respectively, in combination with insulin.